Biohope recognized as a TOP 10 In Vitro Diagnostic Solution Providers in Europe 2020

Published On: March 23rd, 2020

To help healthcare organizations select the best IVD Companies, a distinguished panel comprising CEOs, CIOs, VCs, industry analysts, and MedTech Outlook’s editorial board has narrowed down a list of IVDs solution providers who are on the forefront of innovative technologies and strategies.

As a result, Biohope, an early commercial stage R&D company dedicated to the development of precision medicine IVD tools in the field of Immunology and diseases in which the immune system is a key player, has been recognized as one of the TOP 10 IN VITRO DIAGNOSTIC SOLUTION PROVIDERS IN EUROPE – 2020.

Congratulations on being part of this honored list of companies.

Download certificaded pdf

“…Touted as the biggest innovation in transplantation in the last 15 years, IMBG has been clinically tested in patients after more than one year of kidney transplantation, as a major challenge for clinicians is to improve graft survival after one year and reduce the risk of rejection.”

“The buoyant Biohope team, with a definite focus on research and development, is firing on all cylinders to come up with more innovative products that are beneficial to the medical fraternity. With IMMUNOBIOGRAM for kidney transplantation ready for commercialisation, the next step for Biohope is to adapt and validate the technology for other indications like liver transplants, rheumatoid arthritis and lupus.

The company’s short-term plans on the anvil include forging strategic partnerships and expanding into Europe, North America and APAC in the next three years.”